Health Care [ 9/12 ] | Biotechnology [ 38/73 ]
NASDAQ | Common Stock
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer.
Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 12, 25 | -0.51 Decreased by -34.21% | -0.48 Decreased by -6.25% |
| Mar 10, 25 | -0.48 Decreased by -26.32% | -0.37 Decreased by -29.73% |
| Dec 19, 24 | -0.34 Increased by +10.50% | -0.36 Increased by +5.56% |
| Sep 10, 24 | -0.32 Increased by +30.43% | -0.35 Increased by +8.57% |
| Jun 30, 24 | -0.38 Increased by +17.70% | -0.26 Decreased by -46.15% |
| Jun 14, 24 | -0.38 Increased by +91.58% | -0.27 Decreased by -40.74% |
| Jun 14, 24 | -0.38 Increased by +91.58% | - |
| Mar 11, 24 | -0.46 Decreased by -14.74 K% | -0.47 Increased by +2.13% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Apr 30, 25 | 0.00 Decreased by N/A% | 25.82 M Increased by +272.28% | Increased by +N/A% Decreased by N/A% |
| Jan 31, 25 | 0.00 Decreased by N/A% | -24.62 M Decreased by -129.82% | Decreased by N/A% Decreased by N/A% |
| Oct 31, 24 | 0.00 Decreased by N/A% | -15.30 M Increased by +81.46% | Decreased by N/A% Decreased by N/A% |
| Jul 31, 24 | 0.00 Decreased by N/A% | -14.15 M Decreased by -199.75% | Decreased by N/A% Decreased by N/A% |
| Apr 30, 24 | 0.00 Decreased by N/A% | -14.98 M Decreased by -183.68% | Decreased by N/A% Decreased by N/A% |
| Jan 31, 24 | 0.00 Decreased by N/A% | -10.71 M Decreased by -44.39% | Decreased by N/A% Decreased by N/A% |
| Oct 31, 23 | 0.00 Decreased by N/A% | -82.50 M Decreased by -886.10% | Decreased by N/A% Decreased by N/A% |
| Jul 31, 23 | 0.00 Decreased by N/A% | -4.72 M Increased by +30.04% | Decreased by N/A% Decreased by N/A% |